ADIPOQ and type 2 diabetes mellitus: Several studies in humans and rodents confirmed that obesity [42], T2DM [43], hypertension [44], atherosclerosis [45], CAD [46], MI [47] and HF [46] are associated with reduced plasma adiponectin levels and/or impaired adiponectin signaling in target tissues.